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Introduction
Hyperglycaemia, hypoglycaemia, and glycaemic instability 
are common in preterm infants and have been associated 
with increased risk of mortality and morbidity.1–5 Hyper­
glycaemia can lead to acute problems of osmotic diuresis 
and metabolic acidosis, and has been associated with 
increased risk of intraventricular haemorrhage,5 patent 
ductus arteriosus, retinopathy of prematurity,1 necrotising 
enterocolitis,3 and a reduction in white matter.6 Attempts to 
reduce risks associated with hyperglycaemia can increase 
the risk of hypoglycaemia,7 which has been associated with 
poor developmental outcomes.4
However, maintaining normoglycaemia in preterm 
infants is challenging due to the highly variable com­
bination of insulin resistance and insulin de ficiency, 
as well as low energy reserves in individual babies. 
The current practice of infrequent, intermittent blood 
glucose measurement adds to the difficulties of avoiding 
extremes of blood glucose concentrations.8 Furthermore, 
studies using masked subcutaneous continuous glucose 
monitoring (CGM) have shown extended episodes of both 
hyperglycaemia and hypo glycaemia that were clinically 
silent but were associated with worse develop mental 
outcomes in childhood.9,10
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Summary
Background Hyperglycaemia and hypoglycaemia are common in preterm infants and have been associated with 
increased risk of mortality and morbidity. Interventions to reduce risk associated with these exposures are particularly 
challenging due to the infrequent measurement of blood glucose concentrations, with the potential of causing more 
harm instead of improving outcomes for these infants. Continuous glucose monitoring (CGM) is widely used in 
adults and children with diabetes to improve glucose control, but has not been approved for use in neonates. The 
REACT trial aimed to evaluate the efficacy and safety of CGM in preterm infants requiring intensive care.
Methods This international, open-label, randomised controlled trial was done in 13 neonatal intensive care units in 
the UK, Spain, and the Netherlands. Infants were included if they were within 24 h of birth, had a birthweight of 
1200 g or less, had a gestational age up to 33 weeks plus 6 days, and had parental written informed consent. Infants 
were randomly assigned (1:1) to real-time CGM or standard care (with masked CGM for comparison) using a central 
web randomisation system, stratified by recruiting centre and gestational age (<26 or ≥26 weeks). The primary efficacy 
outcome was the proportion of time sensor glucose concentration was 2·6–10 mmol/L for the first week of life. Safety 
outcomes related to hypoglycaemia (glucose concentrations <2·6 mmol/L) in the first 7 days of life. All outcomes 
were assessed on the basis of intention to treat in the full analysis set with available data. The study is registered with 
the International Standard Randomised Control Trials Registry, ISRCTN12793535.
Findings Between July 4, 2016, and Jan 27, 2019, 182 infants were enrolled, 180 of whom were randomly assigned 
(85 to real-time CGM, 95 to standard care). 70 infants in the real-time CGM intervention group and 85 in the standard 
care group had CGM data and were included in the primary analysis. Compared with infants in the standard care 
group, infants managed using CGM had more time in the 2·6–10 mmol/L glucose concentration target range (mean 
proportion of time 84% [SD 22] vs 94% [11]; adjusted mean difference 8·9% [95% CI 3·4–14·4]), equivalent to 
13 h (95% CI 5–21). More infants in the standard care group were exposed to at least one episode of sensor glucose 
concentration of less than 2·6 mmol/L for more than 1 h than those in the intervention group (13 [15%] of 85 vs 
four [6%] of 70). There were no serious adverse events related to the use of the device or episodes of infection.
Interpretation Real-time CGM can reduce exposure to prolonged or severe hyperglycaemia and hypoglycaemia. 
Further studies using CGM are required to determine optimal glucose targets, strategies to obtain them, and the 
potential effect on long-term health outcomes.
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Therefore, improving early glucose control might be 
an important modifiable risk factor for outcomes in 
preterm infants. The development of real­time CGM, 
which provides continuous glucose data and identifies 
early trends in glucose concentrations can inform 
clinical decisions, and has been successfully used in 
adult11 and paediatric intensive care.12–14 Preliminary data 
suggest it is feasible in preterm infants10,15–17 and could 
allow earlier detection and potentially prevention of 
exposure to extreme glucose concentrations.17,18 We aimed 
to formally evaluate the use of real­time CGM to guide 
the clinical management of glycaemic control and use of 
insulin in preterm infants. 
Methods
Study design and participants
This was an international, open­label, parallel­group, 
randomised controlled trial done in 13 neonatal intensive 
care units in the UK, Spain, and the Netherlands. Infants 
were included if they were within 24 h of birth, had a 
birthweight of 1200 g or less, had a gestational age up to 
33 weeks plus 6 days, and had parental written informed 
consent. Exclusion criteria included any lethal congenital 
malformations or congenital metabolic disorders. The 
trial was reviewed and approved in the UK by the Health 
Research Authority (IRAS ID 168042), Research Ethics 
Committee (reference 15/EE/0158), and the Medicines 
and Healthcare products Regulatory Agency (reference 
CI/2016/0011), as well as by all local regulatory boards. 
International regulatory approvals were obtained for non­
UK sites. The study was coordinated and monitored by 
the National Institute for Health Research Cambridge 
Clinical Trials Unit (Cambridge, UK) in accordance with 
international guidelines. An independent data monitoring 
and ethics committee and a trial steering committee were 
appointed and reviewed the data according to their formal 
charters. The protocol has been published elsewhere.19
Randomisation 
Babies were randomly assigned (1:1) within 24 h of birth 
to receive either the intervention with real­time CGM or 
standard care until 7 days of age.19 Randomisation was 
done using a central web randomisation system, Trans 
European Network ALEA, using blocks of random size 
(four, six, eight), stratifying by recruiting centre and 
gestational age (<26 or ≥26 weeks). Masking of the study 
intervention was not feasible.
Procedures
All infants had an Enlite glucose sensor (Medtronic, 
Northridge, CA, USA) inserted subcutaneously into 
the thigh. Sensors were inserted by hand, not using the 
standard insertion device, to ensure that they were 
inserted into the subcutaneous tissue. A blood glucose 
Research in context
Evidence before this study
Both hyperglycaemia and hypoglycaemia are common in 
preterm infants and are associated with mortality and 
morbidity. Management is challenging because high energy and 
nutritional requirements are needed to support growth, 
and variable insulin sensitivity makes infants at risk from both 
hyperglycaemia and hypoglycaemia. Hyperglycaemia can lead to 
acute problems of osmotic diuresis and metabolic acidosis, 
and has been associated with increased risk of intraventricular 
haemorrhage, retinopathy of prematurity, and necrotising 
enterocolitis. Continuous glucose monitoring (CGM) has shown 
that periods of clinically silent hypoglycaemia are associated 
with later impaired developmental outcomes. The use of CGM in 
vulnerable preterm infants could allow earlier detection and 
potentially prevention of exposure to extreme glucose 
concentrations. Real-time CGM has been used in adult and 
paediatric intensive care to optimise glucose control, 
and preliminary data suggest it is feasible in preterm infants. 
We searched PubMed, Cochrane Library, and clinical trials 
databases on Oct 31, 2014, using the search terms “continuous 
glucose monitoring”, “preterm”, “hyperglycemia”, 
and “hypoglycemia” for clinical trials published between 1966, 
and Oct 31, 2014, with no language restrictions. There were no 
randomised controlled trials of real-time CGM in preterm 
infants; however, an updated search in October, 2020, identified 
four small, single-centre, randomised studies exploring the 
feasibility of using CGM to target glucose control, but this has 
not been formally evaluated as part of a multicentre trial.
Added value of this study
To our knowledge, this is the first multicentre trial to evaluate 
the efficacy, safety, and use of CGM in preterm infants by 
allowing clinicians to use CGM data to optimise nutritional 
delivery as well as providing guidance on using insulin. We show 
that real-time CGM can improve the targeting of glucose control 
in preterm infants, with increased time in the target glucose 
concentration range of 2·6–10 mmol/L compared with standard 
care. This was achieved by reducing the number of infants 
exposed to prolonged or severe hyperglycaemia and episodes of 
hypoglycaemia lasting more than 1 h. The exploratory finding 
that the rate of necrotising enterocolitis was higher in the 
standard care group than in the real-time CGM group warrants 
further investigation. Although the real-time CGM device was 
not designed for use in newborn infants, there were no reported 
serious adverse effects.
Implications of all the available evidence
This study supports the clinical use of CGM in preterm infants to 
optimise nutritional delivery alongside improving glucose 
monitoring and management. CGM can provide more targeted 
glucose control with less invasive blood glucose testing. Further 
studies will be important to evaluate the longer-term effect on 
clinical outcomes.
For more on ALEA see 
https://www.aleaclinical.eu/
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sample was required every 12 h for calibration and each 
neonatal intensive care unit was provided with Nova 
StatStrip meters (Nova Biomedical, Waltham, MA, USA) 
to provide consistency in this measure across sites. 
Clinical outcome data were collected until 36 weeks’ 
corrected gestational age. The real­time CGM system 
comprised an Enlite sensor and a Guardian 2 Link 
transmitter (Medtronic, Northridge, CA, USA), linking to 
a 640G monitor (MiniMed 640G, Medtronic, Northridge, 
CA, USA). The system was used solely to monitor the 
glucose concentrations as described previously.20 Glucose 
concentrations outside the range 2·2–22·2 mmol/L 
(40–400 mg/dL) are recorded by the monitor as less than 
2·2 mmol/L (40 mg/dL), or more than 22·2 mmol/L 
(400 mg/dL). The system is not licensed for use in 
neonatal intensive care.
For infants assigned to the intervention group, the real­
time CGM data were available to view by the clinical team 
during the first week of life. Clinical staff were advised to 
read and record the sensor glucose data hourly and were 
provided with a specifically designed guideline to aid the 
management of glucose control on the basis of the CGM 
data. This included modification of the rate of dextrose 
infusion or use of supplementary insulin. This guidance 
was developed during the REACT feasibility study,18 
and provides advice based on trends as well as absolute 
glucose concentrations (appendix p 2). The clinical 
decision making, including changes in dextrose and 
insulin infusion, was based primarily on the real­time 
CGM data but the guideline advised checking blood 
glucose concentrations when there were rapid changes 
in CGM values, or if CGM values fell to less than 
4 mmol/L to ensure safety. Considering the feedback 
from the feasibility study, the threshold and prediction 
alarms on the real­time CGM devices were switched off.18 
All other aspects of clinical care were at the discretion of 
local staff.
Infants assigned to the control group had glucose 
control monitored and managed according to local 
standard clinical practice using intermittently sampled 
blood glucose concentrations. All aspects of clinical 
care were at the discretion of local staff. The real­time 
CGM device collected glucose data continuously but the 
values were masked to the clinical team (in an opaque 
bag with a tamper proof seal). Calibration was required 
every 12 h, and compliance was documented with a log 
that recorded timings of the tamper tag being broken 
and resealed.
Outcomes
The primary efficacy outcome was the proportion of 
time that sensor glucose concentrations were in the 
target range of 2·6–10 mmol/L up to 7 days of life, 
compared between study groups. This was selected as 
the most widely accepted international target for glucose 
control in this population,21 outside of which clinical 
intervention would be put in place due to associated 
adverse effects. Secondary efficacy outcomes were: the 
proportion of time sensor glucose concentrations were 
in the target range of 4–8 mmol/L; overall mean sensor 
glucose concentration, sensor glucose concentration 
variability (assessed by within­patient standard devi­
ation), and proportion of time that sensor glucose 
concen trations were in the severe hyperglycaemic range 
(>15 mmol/L). Safety outcomes were incidence of 
hypoglycaemia (any recorded blood glucose concen­
tration of 2·2–2·6 mmol/L  or any continuous episode 
of sensor glucose concentration of <2·6 mmol/L for 
>1 h) and severe hypoglycaemia (any recorded blood 
glucose ≤2·2 mmol/L). 
Predefined exploratory analyses were done on clinical 
outcomes: mortality before 36 weeks’ corrected ges­
tational age; retinopathy of prematurity (maximum 
grade across all examinations); bronchopulmonary dys­
plasia (need for supplemental oxygen or respiratory 
support at 36 weeks’ corrected gestational age); infection 
(microbiologically confirmed or clinically suspected late 
See Online for appendix
Figure: Trial profile
All infants who were consented, with the exception of the three ineligible 
infants, were included in the safety analysis. CGM=continuous glucose 
monitoring.
70 had CGM data and included in
the primary and secondary
analyses
14 had no CGM data
77 reached day 7 and day 14
7 withdrawn
75 reached 36 weeks’ corrected
gestation
2 died
85 had CGM data and included in
the primary and secondary
analyses
10 had no CGM data





2 excluded >24 h old
1 ineligible
95 assigned standard care
85 reached 36 weeks’ corrected
gestation
4 died
182 consented and enrolled
1350 infants screened
360 eligible within 24 h of birth
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onset invasive infection from trial entry until hospital 
discharge); necrotising enterocolitis (requiring surgical 
intervention including peritoneal drainage or causing 
death); patent ductus arteriosus (requiring medical 
or surgical treat ment); intracerebral pathology before 
discharge; growth at the end of week 1 and at 36 weeks’ 
corrected gestational age; nutritional intake in week 1; 
and use of insulin in weeks 1 and 2.19 The use of real­
time CGM was assessed using a questionnaire, which 
was completed anonymously by staff caring for an 
infant on days 3 and 7 (to provide an unbiased sample), 
and a similar parent questionnaire completed on day 7. 
A prospective economic evaluation was done as an 
exploratory analysis and will be reported elsewhere. All 
outcomes were centrally assessed.
Statistical analysis
The sample size was based on data from the REACT 
feasibility study and historical control data,10,18 which 
conservatively assumed that the SD of the primary 
endpoint would be 22%. Initially, a sample size of 
200 partici pants was calculated to be needed to detect 
a treatment effect of a 10% increase in the mean value of 
the primary endpoint with 90% power using a two­sided 
5% significance test in the primary analysis. Based on 
a consensus of expert opinion on the trial steering 
committee, a difference of 10% was thought to be of 
clinical relevance. Recruitment rates were lower than 
expected and an interim masked analysis was done in 
March, 2018, after 82 infants had been recruited. The 
revised estimate of the SD for the primary endpoint 
(16·6, 95% CI 14·0–20·6) suggested that the original 
sample size would provide 92·5% power, whereas 
concluding the study with 182 patients rather than the 
planned 200 would reduce the conservative estimate 
of power from 92·5% to 90%. The data monitoring 
and ethics committee and the trial steering committee 
decided that this would be an acceptable compromise to 
be able to report trial results within the desired timelines. 
The trial steering committee therefore recommended 
that the sponsor suspend recruitment when 182 infants 
had been recruited.
Analyses were predetermined in the statistical analysis 
plan to compare real­time CGM intervention with 
standard care. All analyses were done in the full analysis 
set with available data on an intention­to­treat basis. 
Linear regression was used to estimate the absolute 
difference in the proportion of time sensor glucose 
concentration in the target range of 2·6–10 mmol/L, 
adjusting for baseline variables (centre and gestational 
age). Secondary and exploratory endpoints that were 
continuous variables were analysed in the same way, and 
binary or ordinal variables were analysed using logistic 
or ordinal logistic regression.
To control the study­wide significance level to 5%, 
a Benjamini­Hochberg multiple testing procedure was 
applied to three endpoints of equal importance (pro­
portion of time the sensor glucose concentration was 
2·6–10 mmol/L, proportion of time the sensor glucose 
concentration was 4–8 mmol/L, and mean sensor 
glucose concentration). This was followed by a gate­
keeping sequence applied to the remaining two variables, 
sensor glucose variability within individuals and pro­
portion of time that sensor glucose concentrations were 
in the hyper glycaemic range (>15 mmol/L). Estimates 
of treat ment effect, with 95% CIs and adjusted p values, 
were calculated. The primary and secondary efficacy 
analyses used all available sensor glucose measurements 
for each infant. Sensitivity analyses of the primary 
outcome were: linear regression adjusted for time to 
first sensor glucose measurement and the first sensor 
glucose value recorded; linear regression weighted 
by the number of CGM measurements per infant; 
generalised least squares regression allowing variance to 
differ between treatment groups; and a random effects 
model with a random intercept for site. 
This study is registered with the International Standard 
Randomised Controlled Trial Registry, ISRCTN12793535.
CGM group (n=84) Standard care group 
(n=95)
Gestational age, weeks
Mean 27·7 (2·1) 27·4 (1·9)
Range 24·0–33·7 23·3–31·3
Birthweight, g 910 (160) 880 (180)
Birthweight SD score –0·82 (0·98) –0·80 (0·92)
Sex
Male 45 (54%) 45 (47%)
Female 39 (46%) 50 (53%)
Ethnicity*
Asian 7 (8%) 11 (12%)
Black 7 (8%) 8 (8%) 
Mixed 6 (7%) 5 (5%) 
Other 3 (4%) 5 (5%) 
White 61 (73%) 66 (69%) 
Number of infants delivered
Singleton 65 (77%) 70 (74%) 
Multiple 19 (23%) 25 (26%) 
Mean CRIB II score† 10 (2·9) 10 (2·9)
Received antenatal steroids more than 24 h before delivery 69 (82%) 69 (73%)
Received antibiotics within 24 h of delivery 25 (30%) 32 (34%)
Maternal diabetes 5 (6%) 8 (8%)
Maternal chorioamnionitis 19 (23%) 21 (22%)
Delivery mode
Spontaneous vaginal delivery 29 (35%) 31 (33%) 
Caesarean section before onset of labour 41 (49%) 40 (42%) 
Caesarean section after onset of labour 13 (15%) 22 (23%) 
Assisted vaginal delivery 1 (1%) 2 (2%)
Data are mean (SD), range, or n (%). CGM=continuous glucose monitoring. CRIB=Clinical Risk Index for Babies. 
*Ethnicity was parent-reported. †For CRIB II score, data are available for n=91 in the standard care group and n=80 in 
the CGM group. 
Table 1: Baseline characteristics
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Role of the funding source
Neither the funders nor sponsor had any role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. Raw data was accessible to the 
trial statisticians and data team (SB, AA, BP, SK, SP). All 
authors had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Between July 4, 2016, and Jan 27, 2019, 360 newborn 
infants deemed eligible on the basis of birthweight 
(≤1200 g) were identified within 24 h of birth, and 182 
were enrolled in the trial after their parents consented, 
giving a consent rate of 51%. There was a short recruitment 
window and some families could not be approached 
because the parents were not available or there were no 
available research staff during the 24 h after birth (figure). 
180 infants were randomly assigned, 85 to intervention 
with real­time CGM and 95 to standard care. There were 
11 withdrawals from the trial and eight deaths (intervention 
n=2, standard care n=6); one infant in the CGM group 
was later found to be ineligible because they were older 
than 24 h and they were excluded from the study and 
analysis. Baseline characteristics of all infants eligible 
after randomisation are shown in table 1. CGM data were 
collected for 155 patients (intervention n=70, standard care 
n=85; distribution by centre shown in appendix p 7). 
Two infants were randomly assigned but were withdrawn 
before sensor insertion. The mean number of CGM data 
points in the real­time CGM intervention group was 1538 
(SD 341) and in the standard care group was 1412 (424). 
The distribution of glucose concentrations recorded on 
the CGM devices in the two study groups is shown in 
appendix p 3.
The primary outcome, proportion of time that sensor 
glucose concentrations were 2·6–10 mmol/L, was 94% 
(SD 11) in the real­time CGM group and 84% (22) in 
the standard care group (table 2). The intervention with 
real­time CGM compared with standard care increased 
the time that sensor glucose concentration was in the 
target range by 8·9 percentage points (95% CI 3·4–14·4; 
adjusted p=0·005). This is equivalent to an increase of 
13 h (95% CI 5–21) within the target range during the 
first 6 days of life. Sensitivity analyses showed similar 
treatment effects, suggesting the results are robust 
(appendix pp 10–13).
Secondary outcome analyses showed an increase of 
11·5 percentage points (95% CI 3·7–19·2; adjusted 
p=0·006) in the proportion of time in the target range 
of 4–8 mmol/L, equivalent to 17 h (95% CI 5–28), in 
the real­time CGM intervention group compared with the 
standard care group. Mean sensor glucose concentration, 
sensor glucose concentration variability, and the pro­
portion of time that sensor glucose concentration was 
more than 15 mmol/L did not differ significantly between 
the two groups (table 2).
The results of the exploratory analyses are shown in 
table 3 and the appendix (p 8). More infants in the real­
time CGM intervention group (49 [61%] of 80) received 
insulin in the first week of life than those in the standard 
care group (35 [37%] of 94); however, there was no 
signifi cant difference in total insulin infused between 
the two groups (table 3). Infants in the real­time CGM 
intervention group received more infused daily glucose 
than infants in the standard care group (mean difference 
0·69 g/kg; 95% CI 0·02–1·35). The incidence of necro­
tising enterocolitis was lower in the real­time CGM 
intervention group (10 [13%] of 75 infants) than in the 
standard care group (24 [28%] of 85; adjusted odds ratio 
[OR] 0·33; 95% CI 0·13–0·78); for the other exploratory 
clinical outcomes, no significant differences between 
groups were seen (appendix p 8).
There was no significant difference between the 
two groups for any of the safety analyses (appendix p 9): at 
least one episode of severe hypoglycaemia (blood glucose 
concentration of ≤2·2 mmol/L) was recorded in ten (13%) 
of 75 infants in the intervention group and in six (7%) of 
93 infants in the standard care group; at least one episode 
blood glucose concentration of 2·2–2·6 mmol/L was 
recorded in 11 (15%) of 75 infants in the intervention 
group and in 11 (12%) of 93 infants in the standard care 
group. Among infants with CGM data, four (6%) of 70 in 
the intervention group and 13 (15%) of 85 in the standard 
care group a had at least one episode of sensor glucose 
CGM group 
(n=70)






Proportion of time sensor glucose was 2·6–10 mmol/L
Mean 94% (11) 84% (22) 8·9% (3·4 to 14·4) 0·005
Median 99% (92–100) 97% (71–100) ·· ··
Proportion of time sensor glucose was 4–8 mmol/L
Mean 74% (20) 62% (29) 11·5% (3·7 to 19·2) 0·006
Median 78% (61–89) 65% (39–88) ·· ··
Sensor glucose concentration, mmol/L
Mean 6·5 (1·2) 7 (2·1) –0·46 (–1·00 to 0·09) NA
Median 6·4 (5·8–9·9) 6·5 (5·2–8·4) ·· ··
Sensor glucose variability
Mean 2·7 (3·0) 3·6 (4·3) –0·01 (–0·15 to 0·13) NA
Median 1·9 (1·1–3·2) 2·1 (1·1–4·2) ·· ··
Proportion of time in hyperglycaemic range (sensor glucose >15 mmol/L)
Mean 0·3% (2·1) 1·3% (4·2) –0·92% (–2·03 to 0·19) NA
Median 0·0% (0·0–0·0) 0·0% (0·0–0·0) ·· ··
Proportion of time in hypoglycaemic range (sensor glucose <2·6 mmol/L)
Mean 1·0 (5·3) 1·1 (3·2) –0·09 (–1·52 to 1·33) NA
Median 0·0 (0·0–0·2) 0·0 (0·0–0·1) ·· ··
Data are mean (SD) or median (IQR), unless indicated otherwise. *Adjusted for gestation and centre. †Adjusted for 
Benjamini-Hochberg test procedure. CGM=continuous glucose monitoring. NA=not applicable (due to the multiple 
testing procedure, p values are only reported up to the first non-significant p value).
Table 2: Primary and secondary efficacy outcomes
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concentration of less than 2·6 mmol/L for more than 1 h; 
mean total time with a sensor glucose concentration of 
less than 2·6 mmol/L was 0·5 h (SD 1·7) in the real­time 
CGM intervention group and 1·0 h (3·2) in the standard 
care group. There were no serious adverse events related 
to the use of the device or episodes of infection and the 
device did not appear to cause any discomfort.
Staff and parents reported that the real­time CGM did 
not interfere with the infants’ care or cause any distress. 
Moreover, 35 (80%) of 44 parents and 74 (70%) of 106 staff 
reported that the use of CGM improved clinical care 
(appendix pp 4–5). Staff reported an increase in work 
load, although the free text included in the questionnaire 
suggested this related to the paperwork associated with 
trial data collection rather than the intervention per se. 
The time interval between blood glucose measurements 
did not differ between the two groups: mean 7·1 h 
(SD 4·7) in the intervention group versus 5·7 h (4·4) in 
the standard care group.
Discussion
This multicentre study shows that intervention with real­
time CGM, even outside centres with previous experience 
or special interest in the use of CGM, can improve 
glucose control in preterm infants. Compared with 
the standard care group, infants in the real­time CGM 
intervention group had reduced exposure to prolonged or 
severe hyperglycaemia and hypoglycaemia, which has 
implications for long­term health outcomes. Furthermore, 
staff and parents felt that the intervention improved care.
High energy and nutritional requirements and variable 
insulin sensitivity in preterm infants makes preventing 
hyperglycaemia, without the risk of hypoglycaemia, 
challenging. Although reducing dextrose infusion rates 
can ameliorate hyperglycaemia, glucose supply seems to 
have only a limited effect on blood glucose concen­
trations.16,22 Insulin treatment can help to maintain 
normo glycaemia while supporting optimal nutritional 
delivery, and insulin treatment has been associated 
with lower mortality in infants with hyperglycaemia.23 
However, substantial concern remains about the safety 
of insulin due to the risk of hypoglycaemia using 
current intermittent blood glucose monitoring. This 
study supports previous single­centre studies using real­
time CGM in newborn infants but is unique in allowing 
clinicians to use the CGM data to optimise nutritional 
delivery as well as providing guidance on using insulin.24
This study also included the most preterm infants, as 
it is these infants who are most at risk of glucose 
dysregulation, and in whom improvements in glycaemic 
control could have the most impact on morbidity and 
mortality. We did exploratory analyses to determine the 
effects of improved glucose control in our cohort. Fewer 
babies in the real­time CGM intervention group died 
than in the control group but the study was not powered 
to show differences in mortality. Although the study was 
also underpowered to show differences in morbidity 
outcomes, one relevant outcome was the higher rate of 
necrotising enterocolitis in the standard care group than 
in the real­time CGM intervention group. Data have 
shown a causal pathway linking hyperglycaemia to an 
increased risk of microbial gut translocation in both 
animal models and adult studies.25 With necrotising 
enterocolitis being a major cause of mortality and 
morbidity this is a relevant finding, but larger studies 
would be needed to confirm the link. There is also good 
animal and human evidence to link hyperglycaemia with 
retinopathy of prematurity, bronchopulmonary dysplasia, 
and intraventricular haemorrhage and reduced white 
matter at term, but our exploratory analyses of these 
relationships were not significant.
Any benefits in terms of clinical outcomes might 
be related to glucose concentrations per se or to the 
resulting clinical decision­making and interventions. 
The increased time in target glucose concentration 
range in the intervention group was associated with a 
larger number of infants receiving insulin than in the 
standard care group, although there was no difference in 
the total amount of insulin infused between the groups. 
There was also a significant increase in amount of 
glucose infused in the intervention group, although this 
remained within the recom mended range of glucose 
requirements for these infants. Together these findings 
suggest less insulin resistance in the infants in the real­
time CGM group than in the standard care group. 
Reduced insulin resistance in the intervention group 









Inotropes 19 (24%) 27 (29%) ·· ··
Antibiotics 75 (94%) 90 (96%) ·· ··
Caffeine 80 (100%) 94 (100%) ·· ··
Morphine 32 (40%) 40 (43%) ·· ··
Corticosteroids 3 (4%) 6 (6%) ·· ··
Insulin 49 (61%) 35 (37%) ·· ··
Nutritional intake
Daily intravenous glucose, g/kg* 9·9 (2·6) 9·2 (2·4) 0·69 (0·02 to 1·35) 0·043
Daily intravenous amino acids, g/kg* 2·2 (1·2) 2·2 (1·3) 0·17 (–0·06 to 0·40) 0·58
Daily intravenous lipids, g/kg* 1·89 (0·77) 1·95 (0·78) –0·04 (–0·21 to 0·13) 0·64
Daily oral nutrition, mL/kg*† 20 (21) 18 (23) 2·0 (–3·6 to 7·6) 0·49
Daily intravenous fluids, mL/kg* 118 (23) 113 (24) NA NA
Total insulin, units per kg per day* 0·60 (0·94) 0·57 (2·14) 0·08 (–3·3 to 3·5) 0·96
Data are n (%) or mean (SD), unless indicated otherwise. Mean differences were adjusted for gestational age and 
centre. CGM=continuous glucose monitoring. NA=not available: daily intravenous fluids were assessed post hoc and 
no statistical comparison was done. *Data available for: daily glucose n=84 in the standard care group, n=81 in the 
GCM group; daily amino acids n=94 in the standard care group, n=81 in the CGM group; daily lipids n=92 in the 
standard care group, n=80 in the CGM group; daily oral nutrition n=94 in the standard care group, n=81 in the CGM 
group; daily intravenous fluids n=94 in the standard care group, n=81 in the CGM group; total insulin n=94 in the 
standard care group, n=80 in the CGM group. †Oral nutrition included expressed maternal milk, donor milk, or preterm 
formula, dependent on availability and maternal preference.
Table 3: Drug and nutritional data in the first week of life
Articles
www.thelancet.com/child-adolescent   Vol 5   April 2021 271
induces insulin resistance,26 and reflects the clinical 
finding that infants who have developed persistent 
hyperglycaemia require higher doses of insulin to regain 
control, and might consequently be at higher risk 
of hypoglycaemia. Further studies will be needed to 
determine the optimal nutritional support and use of 
insulin in these infants, but the use of real­time CGM 
provides the opportunity for such interventions to be 
tested more safely.
As with previous studies, the use of masked CGM 
identified clinically silent episodes of hypoglycaemia.10,24,27 
The CGM data showed numerically more babies in the 
standard care group being exposed to one or more 
episodes of hypoglycaemia for more than 1 h compared 
with those in the intervention group, although the study 
was not powered to detect a statistically significant 
difference. The mean length of time that sensor glucose 
was less than 2·6 mmol/L appeared longer in the 
standard care group than in the real­time CGM 
intervention group. Previous follow­up studies of infants 
with such clinically silent hypoglycaemia have shown 
these silent episodes to be associated with a dose­
dependent increased risk of impaired developmental 
outcomes in childhood.9 The reduction in hyperglycaemia, 
which has been associated with increased risk of multiple 
neonatal morbidities as well as poor growth, also has 
the potential to improve childhood outcomes in the 
long­term.28
Clinical management in the intervention group was 
based on the ability to be guided by trends in glucose 
concentrations shown by the real­time CGM data and 
did not require blood glucose concentrations to be 
checked before altering treatment. However, the advice 
on checking blood glucose concentrations when there 
was a rapid change in CGM values or if CGM values fell 
to less than 4 mmol/L was key to ensuring a safe decision 
system and resulted in unanticipated hypoglycaemia 
being detected. This approach could have resulted in an 
increase in blood glucose measurements, but the time 
interval between point of care blood glucose measure­
ment did not differ between the two groups.
The guideline approach (as shown in appendix p 2) 
within the trial meant that the intervention was 
dependent on clinical nursing staff engagement to take 
on board new technology, to act on the data, and to 
modify management 24 h a day. This makes such an 
intervention challenging to deliver and to show a clinical 
effect. This might be reflected in the staff questionnaire, 
particularly the comments relating to increased work­
load, although the more specific free text comments 
highlighted the workload related to completion of trial 
paperwork rather than the intervention itself. Despite 
these comments and some difficulties with hand in­
sertion of the sensors, the staff and parents reported 
that the real­time CGM improved clinical care (appendix 
pp 4–5). Real­time CGM appeared to be safe for use in 
these preterm infants.
The limitations of this study include the potential 
recruitment bias resulting from a short recruitment 
window due to the desire to optimise early glucose 
control. This early control might be important if insulin 
resistance is to be minimised. There was also more data 
loss than in the feasibility study because of technical 
difficulties with sensor insertion, and because the 
protocol limited repeat insertions.18 Although the tech­
nique of hand insertion is not difficult and, like other 
procedures, becomes easier with experience, this might 
have affected the integrity of the sensor once in place 
and caused a consequent loss of data. Lessons learnt 
during the study in terms of techniques for insertion 
and response to alarms helped to optimise their use. 
Features designed for safety, because CGM devices are 
for personal, independent patient use, led to the need for 
some repeated calibrations and sensor shutting off and 
consequently potentially unnecessary sensor replace­
ment. This highlights the potential benefits of bespoke 
technology for these preterm infants. Repeat insertion 
was limited by the protocol,18 which contrasts with 
similar clinical procedures that are often done more 
than once before being successful. It was not possible to 
mask the clinical or research teams to the study 
intervention, but compliance with masking of the CGM 
in the control group of the study was good. The point 
accuracy of CGM remains controversial but has been 
validated in newborn babies,20 and collecting data by 
CGM in both groups removed any bias associated with 
differences in the frequency of blood glucose sampling.
A further limitation is that this study was not powered 
to show the clinical effect of the difference in hyper­
glycaemia. However, this can be viewed in the context of 
previous studies that have shown that everyday exposure 
to hyperglycaemia (similar to the difference shown in this 
study) increased the risk of retinopathy of prematurity 
independent of the risks associated with decreasing 
gestational age and increasing immaturity (OR 1·073, 
95% CI 1·004–1·146; p=0·04).29 In a large national cohort 
study (EXPRESS), Zamir and colleagues showed that the 
presence of hyperglycaemia more than doubled adjusted 
28­day mortality (OR 2·55; p=0·005).23 Furthermore, 
treating infants who are hyperglycaemic with insulin was 
associated with lower 28­day mortality than not treating 
them (OR 0·15, 95% CI 0·04–0·53; p=0·003).23 Data from 
EXPRESS show the potential effect of not treating babies 
with hyperglycaemia, with those who were untreated for 
1 day having more than 5 times the risk of mortality and 
those who were untreated for 2 days having more than 
7 times the risk of mortality, compared with those who 
were treated.23
In summary, the use of CGM allowed earlier detection 
of and prevention of exposure to the extremes of both 
hypoglycaemia and hyperglycaemia in preterm infants. 
Lessons learnt during the trial will support advances in 
CGM for these babies. Further studies using CGM are 
required to determine optimal glucose targets, strategies to 
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obtain them, and the potential effect on longer term health 
outcomes. The positive engagement of the clinical staff 
supports the potential for CGM to become an established 
part of clinical care as well as a valuable research tool.
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